Clinical Trial Update: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) [Phase 1, Phase 2]

View source ↗

Summary

An early-phase (Phase 1/2) dose-escalation study is investigating intravitreal KIO-301 for Retinitis pigmentosa and choroideremia; the trial is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroideremia
• Retinitis Pigmentosa

Drugs mentioned

• KIO-301 (KIO-301)

Snippet

Sponsor: Kiora Pharmaceuticals, Inc. | Conditions: Retinitis Pigmentosa, Choroideremia | Phase 1, Phase 2 | Status: RECRUITING